Small lymphocytic lymphoma with 17p deletion

Small lymphocytic lymphoma with 17p deletion is an indolent B-cell non-Hodgkin lymphoma primarily affecting the lymphatic and hematopoietic systems in adults, pathologically identical to chronic lymphocytic leukemia but presenting predominantly as lymphadenopathy and splenomegaly rather than peripheral lymphocytosis Consequently, this molecular subtype represents a distinct, high-risk clinical subset requiring non-genotoxic targeted therapies, such as Bruton tyrosine kinase or BCL-2 inhibitors

Small lymphocytic lymphoma with 17p deletion is an indolent B-cell non-Hodgkin lymphoma primarily affecting the lymphatic and hematopoietic systems in adults, pathologically identical to chronic lymphocytic leukemia but presenting predominantly as lymphadenopathy and splenomegaly rather than peripheral lymphocytosis The defining high-risk cytogenetic feature is the loss of the short arm of chromosome 17 [del(17p)], which encompasses the *TP53* tumor-suppressor gene locus Consequently, this molec...

Loss of *TP53* function impairs DNA damage-induced apoptosis, conferring aggressive disease biology, shortened progression-free and overall survival, and marked resistance to conventional DNA-damaging chemoimmunotherapy

Loss of *TP53* function impairs DNA damage-induced apoptosis, conferring aggressive disease biology, shortened progression-free and overall survival, and marked resistance to conventional DNA-damaging chemoimmunotherapy

Consequently, this molecular subtype represents a distinct, high-risk clinical subset requiring non-genotoxic targeted therapies, such as Bruton tyrosine kinase or BCL-2 inhibitors